Welcome to our dedicated page for Atea Pharmaceuticals SEC filings (Ticker: AVIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Atea Pharmaceuticals SEC filings document the regulatory record of a Nasdaq-listed clinical biopharmaceutical company developing oral antiviral therapies. Form 8-K reports furnish financial results, preliminary financial information, business updates, and exhibit press releases that describe the company’s HCV and HEV antiviral programs.
Proxy and annual meeting filings cover governance matters, director elections, auditor ratification, executive compensation, pay-versus-performance disclosures, and stockholder voting results. The filings also identify Atea’s common stock, par value $0.001 per share, traded under AVIR on The Nasdaq Global Select Market.
BML Investment Partners, L.P. and Braden M. Leonard have reported a significant passive ownership stake in Atea Pharmaceuticals, Inc. common stock. As of 12/31/2025, they beneficially owned 7,810,000 shares, representing 9.9% of the outstanding common shares.
Leonard has sole voting and dispositive power over 320,000 shares and shared voting and dispositive power over 7,490,000 shares held by BML Investment Partners, L.P., of which he is the indirect controlling person. They certify the shares are held not for the purpose of changing or influencing control of Atea.
Atea Pharmaceuticals Chief Medical Officer Maria Arantxa Horga reported equity compensation activity involving common stock, restricted stock units (RSUs), and stock options. On January 31, 2026, 41,533 RSUs from a 124,600-unit grant and an additional 9,750 performance-based RSUs vested and were converted into common shares, after which no RSUs remained outstanding from these grants.
On the same date, 51,283 shares of common stock were acquired through an option or RSU-related transaction, and 16,073 shares of common stock were disposed of at $4.24 per share, leaving 96,086 common shares beneficially owned directly. Horga also received a new stock option for 173,500 shares at an exercise price of $4.24, vesting in 48 equal monthly installments starting after January 31, 2026 and becoming fully vested on January 31, 2030.
Atea Pharmaceuticals Chief Commercial Officer John Vavricka reported several equity transactions in the company’s stock. On January 31, 2026, he acquired 42,083 shares of common stock through the vesting and settlement of restricted stock units.
To cover tax obligations, 11,570 shares of common stock were withheld at a price of $4.24 per share, leaving him with 82,594 directly held shares. He also holds 82,508 shares indirectly as trustee of the John F. Vavricka Deed of Trust.
On the same date, Vavricka received a new grant of 119,520 stock options with a $4.24 exercise price. These options vest in 48 equal monthly installments after January 31, 2026 and will be fully vested by January 31, 2030.
Atea Pharmaceuticals Chief Development Officer Janet Hammond reported multiple equity award transactions. On January 31, 2026, 58,050 shares of common stock were acquired through RSU conversions, with 14,136 shares withheld at $4.24 per share to cover taxes, leaving 127,665 common shares directly held.
Concurrent with this, 46,800 RSUs from a 140,400-unit grant that fully vested by January 31, 2026, and 11,250 performance-based RSUs were settled into common stock, reducing RSU holdings to zero. Hammond also received a stock option for 177,000 shares at an exercise price of $4.24 per share, vesting in 48 equal monthly installments after January 31, 2026, and fully vesting on January 31, 2030.
Atea Pharmaceuticals officer Andrea Corcoran reported equity compensation activity. On January 31, 2026, previously granted restricted stock units converted into 54,866 shares of Atea common stock at no cash cost. To cover taxes, 16,104 of these shares were withheld at a price of $4.24 per share.
After these transactions, Corcoran directly owned 763,576 Atea common shares. She also received a new stock option covering 180,000 shares at an exercise price of $4.24 per share. This option vests in 48 equal monthly installments after January 31, 2026 and is fully vested by January 31, 2030.
Atea Pharmaceuticals President, CEO, and Chairman Jean-Pierre Sommadossi reported multiple equity award settlements and an option exercise. On January 31, 2026, 173,466 restricted stock units and 99,517 performance-based RSUs converted into common stock as previously granted awards fully vested.
Also on January 31, 2026, 106,093 shares of common stock were withheld at $4.24 per share to cover tax obligations, leaving 467,830 directly held shares. On February 3, 2026, he exercised a fully vested stock option for 300,000 shares at an exercise price of $1.24 per share, increasing his direct holdings to 767,830 shares. The filing also shows 5,866,025 shares held indirectly through JPM Partners LLC.
Atea Pharmaceuticals EVP and Chief Accounting Officer Wayne Foster reported equity compensation and related share activity. On January 31, 2026, 33,333 and 8,000 restricted stock units (RSUs) converted into an equal number of Atea common shares as vesting and performance conditions were met.
Following these conversions (coded M), Foster held 91,461 common shares before tax withholding. A separate transaction (code F) shows 12,132 shares withheld at $4.24 per share to cover taxes, leaving 79,329 common shares held directly.
Foster also received a new stock option grant for 108,000 shares at a $4.24 exercise price. The option vests in forty‑eight equal monthly installments after January 31, 2026, becoming fully vested on January 31, 2030, with 108,000 options beneficially owned directly after the grant.
Atea Pharmaceuticals, Inc. filed a current report to disclose that it issued a press release with its preliminary unaudited cash and investment balance as of December 31, 2025. The details of this estimated balance are contained in the press release furnished as Exhibit 99.1.
The company emphasizes that this financial information is preliminary, based on currently available data, and remains subject to completion of its fourth-quarter and full-year 2025 financial closing and audit procedures. The information has not been audited or reviewed by its independent registered public accounting firm and is furnished, not filed, meaning it is not subject to certain Exchange Act liability provisions or automatically incorporated into other securities filings.
Atea Pharmaceuticals (AVIR) filed its Q3 2025 10-Q, highlighting continued investment in its hepatitis C program and a strong liquidity position. The company reported a net loss of $42.0 million for the quarter and $113.5 million year-to-date, driven primarily by R&D as Phase 3 trials advance. R&D was $38.3 million in Q3, with HCV external costs a key component.
Cash, cash equivalents and marketable securities totaled $329.3 million as of September 30, 2025, and management believes this will fund operations through 2027. The balance sheet shows total assets of $343.0 million and stockholders’ equity of $315.8 million. Atea completed its $25.0 million share repurchase program in 2025, including 3,054,195 shares bought for $11.4 million in Q3. Shares outstanding were 78,126,796 as of November 10, 2025.
The Phase 3 HCV program (C-Beyond in the US/Canada and C-Forward ex-North America) began enrollment in April and June 2025. Atea maintains an at-the-market facility with Jefferies for up to $200.0 million; no shares were sold as of September 30, 2025. The company previously reduced headcount by ~25%, targeting aggregate savings of approximately $15 million through 2027.
Atea Pharmaceuticals, Inc. (AVIR) furnished its quarterly earnings press release for the three months ended September 30, 2025. The company reported this under Item 2.02 of Form 8-K on November 12, 2025. The press release is furnished as Exhibit 99.1 and incorporated by reference.
The Item 2.02 information, including Exhibit 99.1, is expressly stated as not deemed “filed” under Section 18 of the Exchange Act and not incorporated into Securities Act or Exchange Act filings unless specifically referenced. The filing also lists Exhibit 104 for the cover page Inline XBRL tags.